Primary Malignant Melanoma of the Lung; Case Report of a Rare Entity
DOI:
https://doi.org/10.21276/apalm.3769Keywords:
malignant melanoma, lung, neoplasm, case reportAbstract
Primary pulmonary malignant melanoma is an exceptionally rare non-epithelial neoplasm, constituting around 0.01% of all primary lung malignancies. We report a case of a 57-year-old male with no comorbidities, in whom two nodules were incidentally detected in the middle and lower lobes of the right lung, later diagnosed as primary malignant melanoma of the lung. The prognosis for primary pulmonary malignant melanoma is dismal and many patients have rapid progression and a brief life span, despite intervention. The 5-year survival rate is less than 20%. The survival may range anywhere from a month to 7 years, but averages around 18-20 months according to literature. Our case, however, continues to remain clinically stable till date, presumably due to early detection while the patient was being investigated for an unrelated cause, and timely intervention.References
1. Karimkhani, C., Green, A. C., Nijsten, T., Weinstock, M. A., Dellavalle, R. P., Naghavi, M., & Fitzmaurice, C. (2017, March 30). The global burden of melanoma: results from the Global Burden of Disease Study 2015. British Journal of Dermatology, 177(1), 134-140. doi:https://doi.org/10.1111/bjd.15510
2. Kyriakopoulos, C., Zarkavelis, G., Andrianopoulou, A., Papoudou-Bai, A., Stefanou, D., Boussios, S., & Pentheroudakis, G. (2017). Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review. Case Reports in Oncological Medicine. doi:10.1155/2017/8654326.
3. Sedhai, Y. R., Acharya, R., Bhat, P., Saeed, S., Sohail, H., Kunwar, S., . . . Singh, K. (2025). Primary malignant melanoma of the lung; a case report and literature review. Respiratory Medicine Case Reports, 53. doi:https://doi.org/10.1016/j.rmcr.2024.102161
4. Zhang, X., Wang, Y., & Du, J. (2015). Primary malignant melanoma of left lower lobe of lung: A case report and review of the literature. Oncology Letters, 10(1), 528-530.
5. Gupta, A., Bhattacharya, D., Jain, S., & Suri, J. C. (2015). Primary malignant melanoma of the lung: case report and literature review. The Indian Journal of Chest Diseases & Allied Sciences, 57(3), 181-184.
6. Allen Jr., M. S., & Drash, E. C. (1968, Jan). Primary melanoma of the lung. Cancer, 21(1), 154-9. doi:10.1002/1097-0142(196801)21:1<154::aid-cncr2820210123>3.0.co;2-k
7. Hwang, K., Hwang, K., Jung, J., Oh, S., Park, M., Jeong, Y., . . . Kim, H. (2015). Primary pulmonary malignant melanoma: an unexpected tumor. Tuberculosis and Respiratory Diseases (Seoul), 78(3), 272-275. doi:10.4046/trd.2015.78.3.272.
8. Gong, L. et al. (2012) ‘Primary pulmonary malignant melanoma: A Clinicopathologic study of two cases’, Diagnostic Pathology, 7(1). doi:10.1186/1746-1596-7-123.
9. Perissinotti, A. et al. (2014) ‘Melanoma and nuclear medicine’, Melanoma Management, 1(1), pp. 57–74. doi:10.2217/mmt.14.10.
10. Yamamoto, Y., Kodama, K., Maniwa, T., Takeda, M., Tanaka, Y., Ozawa, K., & Isei, T. (2017). Primary malignant melanoma of the lung: A case report. Molecular and Clinical Oncology, 7 (1), 39 - 41.
11. Yabuki, H., Kuwana, K. and Minowa, M. (2018) ‘Resection of primary malignant lung melanoma: A case report’, Asian Cardiovascular and Thoracic Annals, 26(9), pp. 710–712. doi:10.1177/0218492318811735.
12. Peng, J. et al. (2017) ‘Primary malignant melanoma of the lung’, Medicine, 96(46). doi:10.1097/md.0000000000008772.
13. Mada, P.K., Garibay, M. and Graham, R.L. (2023) ‘Primary malignant melanoma of the lung (PMML); a case report’, Cureus, 15(3). doi:10.7759/cureus.36850.
14. Kirkwood, J.M. et al. (2023) ‘Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial Est 1684’, Journal of Clinical Oncology, 41(3), pp. 425–435. doi:10.1200/jco.22.02264.
15. Strojan, P. (2010) ‘Role of radiotherapy in melanoma management’, Radiology and Oncology, 44(1), pp. 1–12. doi:10.2478/v10019-010-0008-x.
16. Hao, C. et al. (2017) ‘Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 Immunotherapy to advanced melanoma’, Medicine, 96(26). doi:10.1097/md.0000000000007325.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Namrata Mitra, Arpita Sutradhar, Sanjiban Patra, Arindam Sarkar, Puneet Sharma, Arindam Mukherjee
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
How to Cite
